Asia Pacific Structural Heart Market Forecast to 2028 - Regional Analysis - by Product, Procedure, and End User

The Asia Pacific structural heart market is expected to grow from US$ 2,649.67 million in 2022 to US$ 4,374.55 million by 2028. It is estimated to grow at a CAGR of 8.7% from 2022 to 2028.

Technological Advancements in the Field of Structural Heart Devices Fuel Asia Pacific Structural Heart Market

Transcatheter procedures lead to improvements in patients’ heart conditions in shorter a period compared to surgical intervention. In addition, minimally invasive procedures have reduced surgical and cardiopulmonary risks, which results in increased patient satisfaction. TAVR has gathered more attention due to its ability to offer a reasonable option for the treatment of degenerative aortic stenosis. In 2017, the Edwards Lifesciences’s Edwards Sapien valve was under the studies in the PARTNER trial. The valve has been made from a bovine pericardial tissue valve, and it is sutured on a cobalt-chromium stent scaffold. The stent allows the maximum possible folding of the valve, which allows to maintain the structural and radial support once it is expanded. Moreover, the recent developments in structural heart devices focus on indications, and results of left atrial appendage (LAA) and patent foramen ovale (PFO) closure to prevent cardioembolic stroke. A few of the technological advancements by the players in the Asia Pacific Structural Heart Market are mentioned. In February 2023, Medtronic announced the relaunch of its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired RVOT. Evolut FX added new features to the existing Evolut platform to enhance ease of use and predictable valve deployment for physicians. In May 2022, Philips launched EchoNavigator 4.0, the new release of its image-guided therapy solution, for the treatment of structural heart disease. EchoNavigator 4.0 provides the users of Philips’ EPIQ CVXi interventional cardiology ultrasound system a control of live fusion-imaging on the company’s Image Guided Therapy System called “Azurion - platform.” In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform. In August 2021, CORCYM enrolled the first patient in the Mitral, Aortic, and Tricuspid Post-Market Study in a Real-World Setting, i.e., MANTRA. The first implantation was performed at Citta di Lecce Hospital in Italy with a Bicarbon aortic mechanical valve. In August 2021, the first Made in India 3D printed heart valve was developed in Chennai. The new heart valves were developed using 3D printers, which could overcome the problems related to artificial heart valves. Therefore, technological advancements are leading to new growth trends in the Asia Pacific Structural Heart Market growth.

Asia Pacific Structural Heart Market Overview

The Asia Pacific structural heart market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The region holds a significant market share in the global structural heart market. The Asia Pacific structural heart market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, growing cardiovascular diseases, and launch of innovative products by market players in the region.

Asia Pacific Structural Heart Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Structural Heart Market Segmentation

The Asia Pacific structural heart market is segmented into product, procedure, end user, and country.

Based on product, the Asia Pacific structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held the largest share of the Asia Pacific structural heart market in 2022.

Based on procedure, the Asia Pacific structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held the largest share of the Asia Pacific structural heart market in 2022.

Based on end user, the Asia Pacific structural heart market is segmented into hospitals, ambulatory surgical centres, and others. The hospitals segment held the largest share of the Asia Pacific structural heart market in 2022.

Based on country, the Asia Pacific structural heart market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific structural heart market in 2022.

Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, and Lepu Medical Technology Beijing Co Ltd are some of the leading companies operating in the Asia Pacific structural heart market.